Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wenlin Shao

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Science Translational Medicine|May 1, 2020
Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumorsErica Banks, Michael Grondine, Deepa Bhavsar, et al.
Journal for Immunotherapy of Cancer|July 31, 2020
Small molecule AZD4635 inhibitor of A<sub>2A</sub>R signaling rescues immune cell function including CD103<sup>+</sup> dendritic cells enhancing anti-tumor immunityAlexandra Borodovsky, Christine M Barbon, Yanjun Wang, et al.
Journal of Medicinal Chemistry|November 22, 2024
Discovery of (2<i>R</i>,4<i>R</i>)-4-((<i>S</i>)-2-Amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic Acid (AZD0011), an Actively Transported Prodrug of a Potent Arginase Inhibitor to Treat CancerScott N Mlynarski, Brian M Aquila, Susan Cantin, et al.
Journal of Medicinal Chemistry|May 18, 2016
Toward the Validation of Maternal Embryonic Leucine Zipper Kinase: Discovery, Optimization of Highly Potent and Selective Inhibitors, and Preliminary Biology InsightB Barry Touré, John Giraldes, Troy Smith, et al.
Journal of Medicinal Chemistry|September 12, 2018
Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal TumorsJason G Kettle, Rana Anjum, Evan Barry, et al.
Cancer Research|January 19, 2018
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAFWenlin Shao, Yuji M Mishina, Yun Feng, et al.
Journal of Medicinal Chemistry|October 14, 2021
Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target EngagementBernard Barlaam, Chris De Savi, Allan Dishington, et al.
Journal of Medicinal Chemistry|July 13, 2013
Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitorMichael D Shultz, Atwood K Cheung, Christina A Kirby, et al.
Molecular Cancer Therapeutics|March 13, 2023
Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination PartnersAatman S Doshi, Susan Cantin, Marylens Hernandez, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2020
Optimization of a series of potent, selective and orally bioavailable SYK inhibitorsNeil P Grimster, Lakshmaiah Gingipalli, Bernard Barlaam, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Science Translational Medicine|May 1, 2020
Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumorsErica Banks, Michael Grondine, Deepa Bhavsar, et al.
Journal for Immunotherapy of Cancer|July 31, 2020
Small molecule AZD4635 inhibitor of A<sub>2A</sub>R signaling rescues immune cell function including CD103<sup>+</sup> dendritic cells enhancing anti-tumor immunityAlexandra Borodovsky, Christine M Barbon, Yanjun Wang, et al.
Journal of Medicinal Chemistry|November 22, 2024
Discovery of (2<i>R</i>,4<i>R</i>)-4-((<i>S</i>)-2-Amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic Acid (AZD0011), an Actively Transported Prodrug of a Potent Arginase Inhibitor to Treat CancerScott N Mlynarski, Brian M Aquila, Susan Cantin, et al.
Journal of Medicinal Chemistry|May 18, 2016
Toward the Validation of Maternal Embryonic Leucine Zipper Kinase: Discovery, Optimization of Highly Potent and Selective Inhibitors, and Preliminary Biology InsightB Barry Touré, John Giraldes, Troy Smith, et al.
Journal of Medicinal Chemistry|September 12, 2018
Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal TumorsJason G Kettle, Rana Anjum, Evan Barry, et al.
Cancer Research|January 19, 2018
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAFWenlin Shao, Yuji M Mishina, Yun Feng, et al.
Journal of Medicinal Chemistry|October 14, 2021
Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target EngagementBernard Barlaam, Chris De Savi, Allan Dishington, et al.
Journal of Medicinal Chemistry|July 13, 2013
Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitorMichael D Shultz, Atwood K Cheung, Christina A Kirby, et al.
Molecular Cancer Therapeutics|March 13, 2023
Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination PartnersAatman S Doshi, Susan Cantin, Marylens Hernandez, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2020
Optimization of a series of potent, selective and orally bioavailable SYK inhibitorsNeil P Grimster, Lakshmaiah Gingipalli, Bernard Barlaam, et al.
Pageof 4